Fox Business
14 Oct 2026, 03:00 UTC · 2h ago
Johnson & Johnson shares SLIDE nearly 6% despite stronger full-year forecast
Impact · against what's priced in
The raised full-year guidance is a non-event as it simply confirms the current growth trajectory the market already expects. However, the mention of a potential spinoff of DePuy Synthes introduces a new strategic variable that could unlock value or alter the current MedTech valuation.
- JNJ+0.20
Not in the price yet
- The price assumes
OTTAVA surgical robot approval and launch
While the raised guidance is already reflected in the price, the potential spinoff of the DePuy Synthes orthopedics unit is new information that could change how the MedTech segment is valued.
What JNJ's price assumes · Sep 3
Top 1 mover · tap to explore
